A Patient with Metastatic Clear Cell Renal Carcinoma with Long Term Survival Spanning the Era of Pre-Targeted to Molecular Targeted Treatment

Clear Cell Renal Cell Carcinoma (ccRCC) is the most common subtype of kidney cancer, and has the highest risk of developing metastatic disease. Long term survival with durable response remains uncommon despite numerous FDA approved targeted therapies. We report a patient with metastatic ccRCC who survived for 14 years using a number of evolving approaches spanning the pre-targeted era of immunotherapy to present day molecular targeted treatment. These multimodality approaches that included cytoreductive surgery has led to long term survival and a continued high quality of life.